Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleHot Topics

Will GRPR Compete with PSMA as a Target in Prostate Cancer?

Andrei Iagaru
Journal of Nuclear Medicine December 2017, 58 (12) 1883-1884; DOI: https://doi.org/10.2967/jnumed.117.198192
Andrei Iagaru
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 58 no. 12 1883-1884
DOI 
https://doi.org/10.2967/jnumed.117.198192
PubMed 
28970333

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication August 28, 2017
  • Accepted for publication September 13, 2017
  • Published online December 1, 2017.

Article Versions

  • previous version (September 28, 2017 - 05:10).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

Statistics from Altmetric.com

Cited By...

  • 25 Citations
  • 28 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
    Eline A.M. Ruigrok, Wytske M. van Weerden, Julie Nonnekens, Marion de Jong
    Pharmaceutics 2019 11 11
  • Radiolabeled Bombesin Analogs
    Rosalba Mansi, Berthold A. Nock, Simone U. Dalm, Martijn B. Busstra, Wytske M. van Weerden, Theodosia Maina
    Cancers 2021 13 22
  • Radiolabeled PSMA Inhibitors
    Oliver C. Neels, Klaus Kopka, Christos Liolios, Ali Afshar-Oromieh
    Cancers 2021 13 24
  • NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
    Aikaterini Kaloudi, Emmanouil Lymperis, Athina Giarika, Simone Dalm, Francesca Orlandi, Donato Barbato, Mattia Tedesco, Theodosia Maina, Marion De Jong, Berthold Nock
    Molecules 2017 22 11
  • First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9
    Silvano Gnesin, Francesco Cicone, Periklis Mitsakis, Axel Van der Gucht, Sébastien Baechler, Raymond Miralbell, Valentina Garibotto, Thomas Zilli, John O. Prior
    EJNMMI Research 2018 8 1
  • Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
    Benedikt Judmann, Diana Braun, Björn Wängler, Ralf Schirrmacher, Gert Fricker, Carmen Wängler
    Pharmaceuticals 2020 13 8
  • Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
    Fanny Lundmark, Ayman Abouzayed, Bogdan Mitran, Sara S. Rinne, Zohreh Varasteh, Mats Larhed, Vladimir Tolmachev, Ulrika Rosenström, Anna Orlova
    Pharmaceutics 2020 12 7
  • New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer
    Xin Li, Huawei Cai, Xiaoai Wu, Li Li, Haoxing Wu, Rong Tian
    Frontiers in Chemistry 2020 8
  • Prostate Cancer Theranostics - An Overview
    Diane Abou, Nadia Benabdallah, Wen Jiang, Lu Peng, Hanwen Zhang, Alexandria Villmer, Mark S. Longtine, Daniel L. J. Thorek
    Frontiers in Oncology 2020 10
  • Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
    Magdalena Staniszewska, Janette Iking, Katharina Lückerath, Boris Hadaschik, Ken Herrmann, Justin Ferdinandus, Wolfgang P. Fendler
    Nuclear Medicine and Biology 2021 96-97

Article usage

Article usage: September 2017 to April 2025

AbstractFullPdf
Sep 20170022
Oct 201790142
Nov 20173019
Dec 201717732322
Jan 20180234135
Feb 2018016669
Mar 201803659
Apr 201802926
May 201802437
Jun 201801517
Jul 201802812
Aug 20180148
Sep 201802517
Oct 201804029
Nov 201803114
Dec 201802731
Jan 201903533
Feb 201902523
Mar 201903132
Apr 201902625
May 201902522
Jun 201902113
Jul 201902213
Aug 201901611
Sep 201902114
Oct 201902917
Nov 201903722
Dec 201903614
Jan 20200219
Feb 202001114
Mar 202002410
Apr 202002717
May 202001813
Jun 202002312
Jul 20200164
Aug 202003310
Sep 202002110
Oct 202003214
Nov 202001611
Dec 202006022
Jan 202101214
Feb 202101711
Mar 202102921
Apr 202103711
May 202105110
Jun 202103313
Jul 202103618
Aug 202102619
Sep 20210229
Oct 202102524
Nov 202103020
Dec 202102915
Jan 202202912
Feb 20220334
Mar 202203416
Apr 202202415
May 202203012
Jun 202202214
Jul 202203410
Aug 202202119
Sep 202202114
Oct 202203426
Nov 202203114
Dec 20220289
Jan 202304215
Feb 202303311
Mar 202305922
Apr 202304217
May 20230278
Jun 202303512
Jul 20230236
Aug 20230154
Sep 20230339
Oct 20230338
Nov 202303815
Dec 20230294
Jan 20240335
Feb 20240249
Mar 202401439
Apr 202403317
May 20240368
Jun 20240257
Jul 202402015
Aug 20240349
Sep 202402011
Oct 202404713
Nov 202403516
Dec 20240339
Jan 202502222
Feb 202506419
Mar 202503524
Apr 202504623
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (12)
Journal of Nuclear Medicine
Vol. 58, Issue 12
December 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
Andrei Iagaru
Journal of Nuclear Medicine Dec 2017, 58 (12) 1883-1884; DOI: 10.2967/jnumed.117.198192

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
Andrei Iagaru
Journal of Nuclear Medicine Dec 2017, 58 (12) 1883-1884; DOI: 10.2967/jnumed.117.198192
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT
  • Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
  • Google Scholar

More in this TOC Section

  • RECIP 1.0: A Roadmap for Clinical Implementation
  • Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
  • From Stabilization to Depletion: Molecular Imaging to Measure Therapeutic Response in ATTR-CA
Show more Hot Topics

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire